Results 171 to 180 of about 2,626 (203)

Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial

Journal of the American Academy of Dermatology, 2022
Andreas Wollenberg, Andrew E Pink, Le Gjerum   +2 more
exaly  

Safety of tralokinumab in atopic dermatitis

British Journal of Dermatology, 2023
openaire   +2 more sources

Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*

British Journal of Dermatology, 2021
Andreas Wollenberg, Andrew Blauvelt, E Guttman-Yassky   +2 more
exaly  

Tralokinumab ab zwölf Jahren

ästhetische dermatologie & kosmetologie, 2023
openaire   +1 more source

Tralokinumab plus topical corticosteroids for the treatment of moderate‐to‐severe atopic dermatitis: results from the double‐blind, randomized, multicentre, placebo‐controlled phase III ECZTRA 3 trial*

British Journal of Dermatology, 2021
Jonathan I Silverberg, Thomas Bieber, Be Elewski   +2 more
exaly  

Dupilumab/tralokinumab

Reactions Weekly
  +4 more sources

Tralokinumab does not impact vaccine-induced immune responses: Results from a 30-week, randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis

Journal of the American Academy of Dermatology, 2021
Joseph F Merola, Parbeer S Grewal
exaly  

Tralokinumab

Drugs of the Future, 2014
openaire   +1 more source

Tralokinumab for atopic dermatitis: a promising new therapy

British Journal of Dermatology, 2020
D.E. Morra, A.M. Drucker
openaire   +2 more sources

Review of Tralokinumab in the Treatment of Atopic Dermatitis

Annals of Pharmacotherapy, 2023
Rohan Singh, Alexandra Taylor, Steven R Feldman   +2 more
exaly